Your browser doesn't support javascript.
loading
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah, V; Kuravi, S; Ganguly, S; Welch, D R; Vivian, C J; Mushtaq, M U; Hegde, A; Iyer, S; Behrang, A; Ali, S M; Madison, R W; Venstrom, J M; Jensen, R A; McGuirk, J P; Amin, H M; Balusu, R.
Afiliação
  • Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
  • Kuravi S; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA; The University of Kansas Cancer Center, Kansas City, USA.
  • Ganguly S; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA; The University of Kansas Cancer Center, Kansas City, USA.
  • Welch DR; The University of Kansas Cancer Center, Kansas City, USA; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, USA.
  • Vivian CJ; The University of Kansas Cancer Center, Kansas City, USA; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, USA.
  • Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA; The University of Kansas Cancer Center, Kansas City, USA.
  • Hegde A; Department of Hematology/Oncology, University of Alabama, Birmingham, USA.
  • Iyer S; Department of Myeloma and Lymphoma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Behrang A; Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ali SM; Foundation Medicine, Cambridge, USA.
  • Madison RW; Foundation Medicine, Cambridge, USA.
  • Venstrom JM; Foundation Medicine, Cambridge, USA.
  • Jensen RA; The University of Kansas Cancer Center, Kansas City, USA; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA.
  • McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA; The University of Kansas Cancer Center, Kansas City, USA.
  • Amin HM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Balusu R; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA; The University of Kansas Cancer Center, Kansas City, USA. Electronic address: rbalusu@kumc.edu.
ESMO Open ; 6(4): 100172, 2021 08.
Article em En | MEDLINE | ID: mdl-34242968
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Anaplásico de Células Grandes Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Anaplásico de Células Grandes Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article